In the past few decades, tremendous strides have been made in the treatment of adult lymphomas — a group of blood cancers that begin in the white blood cells. Personalized and targeted therapies are resulting in higher success rates and patients surviving and thriving. Ongoing progress continues to offer hope and healing for patients facing this disease.
The University of Chicago Medicine has been at the forefront of this great move forward in lymphoma care. Here, the brightest minds in medicine work every day to advance the care of patients with lymphoma. Our lymphoma experts are committed to developing new therapies for this complex disease and bringing the latest treatments to our patients as quickly as possible. As one of the busiest lymphoma programs in Chicago, we manage care for thousands of patients and see approximately 250 new cases each year.
Specialized Care for High-Risk Lymphomas
Aggressive, high-grade non-Hodgkin lymphomas require prompt care from a team of experts. Our High-Risk Lymphoma Clinic provides focused care for or a variety of fast-growing lymphoma subtypes, including relapsed/refractory aggressive large B-cell lymphomas, Richter's syndrome, relapsed/refractory mantle cell lymphoma and peripheral T-cell lymphomas.
Why Choose Us for Lymphoma Care?
Our hematopathologists (physician-scientists who analyze blood samples and tissue) have extensive knowledge and expertise in identifying lymphoma and accurately pinpointing its different subtypes — some of which are particularly difficult to diagnose. Physicians from around the world regularly consult with our hematopathologists on complicated lymphoma cases.
We take an aggressive approach to treating lymphomas that return after initial treatment. In some cases, stem cell transplantation offers the best chance to cure patients with relapsed lymphoma. Many patients are candidates for outpatient stem cell transplant.
UChicago Medicine had the best one-year stem cell transplant outcomes in Chicago and the highest relative to predicted outcomes, according to recent annual reports from the Center for International Bone and Marrow Transplant Research. Learn about our stem cell transplant outcomes.
We were the first medical center in Illinois to offer CAR T-cell therapy, a breakthrough immunotherapy for the treatment of certain types of non-Hodgkin lymphoma and leukemia. CAR T-cell therapy supercharges the patient’s disease-fighting T-cells to find and destroy cancer cells. Many patients receive CAR T-cell therapy on an outpatient basis, enabling them to return to the comfort of their home in between treatments and appointments.
Lymphomas (Hodgkin and non-Hodgkin) are the third most common cancer in adolescents and young adults. The Adolescent and Young Adult (AYA) Oncology Program at UChicago Medicine addresses the unique needs of this age group.
We offer long-term follow-up and care for adults who were treated for lymphoma as adolescents or young adults. Patients receive an individualized survivorship plan to help them address any medical or psychosocial issues they experience as a result of cancer or its treatment.
The Hoogland Lymphoma Biobank at UChicago Medicine is an innovative new program that links epidemiology (the study of how disease spreads and can be controlled) to malignant lymphoma tissue. The biobank collects and stores donated biospecimens (e.g. tissue, urine, blood) and connects it to personal and medical information. Biobank researchers will examine how lifestyle, occupation, environment and genes affect lymphoma. The goal of the program is to increase understanding of how to prevent, diagnose and treat lymphoma.
CAR T-Cell Therapy
CAR T-cell therapy supercharges a patient's white blood cells to find and destroy cancer cells. UChicago Medicine research played a key role in the development of this exciting new immunotherapy.
View videos and learn more
Lymphoma: News & Patient Stories
